Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes

Eur Arch Psychiatry Clin Neurosci. 2022 May 27. doi: 10.1007/s00406-022-01425-5. Online ahead of print. ABSTRACT Cannabinoid signaling, mainly via CB1 and CB2 receptors, plays an essential role in oligodendrocyte health and functions. However, the specific molecular signals associated with the activation or blockade of CB1 and CB2 receptors in this Read more…

Partage le savoir

Tobacco and Alcohol and Cannabis Experience Questionnaires. Greek translation and test-retest reliability

Psychiatriki. 2022 May 26. doi: 10.22365/jpsych.2022.082. Online ahead of print. ABSTRACT The Tobacco and Alcohol Questionnaire (TAQ) and the Cannabis Experience Questionnaire (CEQ) are two instruments employed in the evaluation of substance use. The First Episode Psychosis (FEP) study in Athens employed two versions of those questionnaires, as part of Read more…

Partage le savoir

Typology of Adolescents Exposed to Non-medical Cannabis Marketing and Associations with Consumption Patterns

Prev Sci. 2022 May 27. doi: 10.1007/s11121-022-01378-0. Online ahead of print. ABSTRACT Latent class analysis (LCA) identified subtypes of cannabis marketing exposure among adolescents and assessed whether the classes were associated with three cannabis use outcomes: past 28-day use, poly-cannabis use, and symptoms of cannabis use disorder (CUD). Survey data Read more…

Partage le savoir

Measuring Impaired Control over Cannabis Use: Initial Evaluation of the Impaired Control Scale-Cannabis (ICS-C)

Subst Use Misuse. 2022 May 27:1-10. doi: 10.1080/10826084.2022.2079137. Online ahead of print. ABSTRACT Background: Impaired control is a central concept in addiction. Impaired control over alcohol has been associated with heavy drinking and alcohol-related problems in young adults, but there is less research on impaired control over cannabis. Currently, there Read more…

Partage le savoir

Efficacy of cannabis and its constituents in disease management: Insights from clinical studies

Curr Med Chem. 2022 May 25. doi: 10.2174/0929867329666220525124818. Online ahead of print. ABSTRACT There is a long history of informal use of Cannabis sativa (commonly called cannabis) for many purposes, including treating various ailments worldwide. However, the legalization of cannabis in multiple countries, specifically for medical purposes, has grabbed the Read more…

Partage le savoir

Altered White Matter Integrity at Illness Onset in Adolescents With a First Episode of Psychosis

Front Psychiatry. 2022 May 10;13:876793. doi: 10.3389/fpsyt.2022.876793. eCollection 2022. ABSTRACT BACKGROUND: Disruption in white matter integrity has been consistently observed in individuals with psychosis. However, whether such abnormalities are already present at illness onset or are related to downstream processes remains elusive. The study of adolescents with a recent onset Read more…

Partage le savoir

Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years

Front Pharmacol. 2022 May 10;13:885655. doi: 10.3389/fphar.2022.885655. eCollection 2022. ABSTRACT A regulatory framework allowing legal access to medicinal cannabis (MC) products has operated in Australia since November 2016. MC prescribing by healthcare practitioners (HCPs) is primarily conducted through the Special Access Scheme – Category B (SAS-B) pathway, through which prescribers Read more…

Partage le savoir

Daily cannabis use, cannabis use disorder, and any medical cannabis use among US adults: Associations within racial, ethnic, and sexual minoritized identities in a changing policy context

Prev Med Rep. 2022 May 13;28:101822. doi: 10.1016/j.pmedr.2022.101822. eCollection 2022 Aug. ABSTRACT Differences in cannabis use patterns among racial, ethnic and sexual minoritized identity subgroups have been attributed to marginalized identity stressors. However, associations at the intersection of these minoritized identities remain underexplored in a changing medical cannabis law (MCL) Read more…

Partage le savoir

Long-term effectiveness and safety of medical cannabis administered through the metered-dose Syqe Inhaler

Pain Rep. 2022 May 17;7(3):e1011. doi: 10.1097/PR9.0000000000001011. eCollection 2022 May-Jun. ABSTRACT INTRODUCTION: Preliminary clinical studies on medical cannabis (MC) treatment using the Syqe Inhaler showed short-term effectiveness and safety at very low and precise doses of MC. OBJECTIVES: Here, we retrospectively analyzed « real-life » long-term data collected in real time on Read more…

Partage le savoir
error: Content is protected !!